Ironwood Pharmaceuticals, Inc. filings document a Nasdaq-listed biotechnology company focused on gastrointestinal and rare disease therapies. Its Form 8-K reports include operating and financial results, business updates for LINZESS and apraglutide, regulatory and pricing matters involving LINZESS, and financing-related disclosures tied to credit agreements and liquidity conditions.
Proxy filings cover board elections, executive compensation votes, equity incentive plan matters, auditor ratification, and annual meeting procedures. Other filings address governance changes, Nasdaq listing-compliance matters for its Class A common stock, and the registered security structure of IRWD shares on the Nasdaq Global Select Market.
Ironwood Pharmaceuticals Chief Legal Officer John Minardo reported automatic sales of 36,492 shares of Class A common stock to cover tax withholding on vested restricted stock units. These open-market transactions occurred on February 23 and 24 at weighted average prices of $3.81 and $3.66 per share, within disclosed intraday price ranges.
After these sell-to-cover trades, Minardo directly held 363,886 Ironwood shares. The filing notes that the sales were executed automatically to satisfy tax obligations and did not represent discretionary trading decisions.
Ironwood Pharmaceuticals SVP and CMO Michael Shetzline reported automatic share sales to cover taxes on vesting restricted stock units. On Class A Common Stock and Common Stock, he sold a total of 32,582 shares in open-market transactions at weighted average prices around $3.81 and $3.66 per share. These sales were executed solely to satisfy tax withholding obligations and were not discretionary trades, and he continued to hold 521,425 shares afterward.
IRONWOOD PHARMACEUTICALS INC Chief Commercial Officer Tammi L. Gaskins reported automatic sales of Class A common stock to cover taxes on vesting restricted stock units. She sold 10,287 shares on February 23 at a weighted average price of $3.81 and 11,239 shares on February 24 at a weighted average price of $3.66, in open-market transactions. The filing states these were mandatory “sell to cover” transactions for tax withholding and not discretionary trades. After these sales, she held 213,738 shares of Ironwood common stock directly.
Ironwood Pharmaceuticals Chief Executive Officer Thomas A. McCourt reported automatic sales of Class A Common Stock to cover tax withholding from vested restricted stock units. On February 23 and 24, 2026, a total of 198,283 shares were sold in open-market transactions classified as non-derivative sales.
The filing notes these were sell-to-cover transactions executed automatically to satisfy tax obligations and did not represent discretionary trades by McCourt. Weighted average sale prices were reported, with shares on one day sold between $3.70 and $4.05 and on the other between $3.60 and $3.73. Following the February 24 sale, he directly held 1,489,002 shares. A footnote also records his acquisition of 4 shares under the company’s employee stock purchase plan on December 31, 2025.
IRONWOOD PHARMACEUTICALS INC Chief Financial Officer Gregory S. Martini reported automatic stock sales to cover taxes tied to restricted stock vesting. On February 23, he sold 10,487 shares of Class A common stock at a weighted-average price of $3.81 per share in open-market transactions within a $3.70–$4.05 range. On February 24, he sold an additional 11,457 shares at a weighted-average price of $3.66 per share within a $3.60–$3.73 range. The filing states these sales were executed automatically solely to satisfy tax withholding obligations and were not discretionary trades. After these transactions, Martini directly owned 160,601 shares of Ironwood Class A common stock.
IRONWOOD PHARMACEUTICALS INC principal accounting officer Ronald Silver reported automatic sales of 24,173 Class A common shares to cover tax withholding obligations from vesting restricted stock units. The transactions involved 11,552 shares on February 23, 2026 at a weighted average price of $3.81 and 12,621 shares on February 24, 2026 at a weighted average price of $3.66. The prices reflect multiple trades within disclosed ranges. After these tax-related, non-discretionary sales, Silver directly held 252,636 shares of Ironwood Pharmaceuticals common stock.
Ironwood Pharmaceuticals reported fourth-quarter and full-year 2025 results and reaffirmed a strong 2026 outlook. For 2025, total revenue was $296.2M, GAAP net income was $24.0M and adjusted EBITDA reached $138.1M. The company generated $127M in operating cash flow and ended the year with $215.5M in cash and cash equivalents.
LINZESS delivered 11% full-year EUTRx demand growth, remaining the leading U.S. prescription brand for IBS-C and CIC. For 2026, Ironwood expects U.S. LINZESS net sales of $1.125–$1.175B, total revenue of $450–$475M and adjusted EBITDA of more than $300M, while it advances the apraglutide Phase 3 STARS-2 trial in short bowel syndrome with intestinal failure.
Ironwood Pharmaceuticals Inc. officer Tammi Gaskins reported a proposed sale of 19,775 Class A common shares, with an approximate sale date of February 23, 2026, and an aggregate market value of $91,162.75. The notice identifies E Trade Securities LLC as the broker and says the shares are to be sold to cover taxes from the vesting of stock awards.
Ironwood Pharmaceuticals Inc. (IRWD) officer Gregory Martini gave notice of a proposed sale of 20,163 shares of Class A common stock, with an aggregate market value of $92,951.43 and an approximate sale date of February 23, 2026. The remarks state that the shares are to cover taxes from vesting stock awards granted by the company.
IRONWOOD PHARMACEUTICALS INC (IRWD) officer Michael Shetzline reported a proposed sale of 29,937 Class A common shares, with an aggregate market value of $138,009.57 and an approximate sale date of February 23, 2026. The remarks state that the shares are being sold to cover taxes from the vesting of stock awards granted by the issuer.